How I treat Waldenström macroglobulinemia
Top Cited Papers
- 5 December 2019
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 134 (23), 2022-2035
- https://doi.org/10.1182/blood.2019000725
Abstract
Waldenström's macroglobulinemia (WM) is an uncommon lymphoma characterized by the infiltration of the bone marrow by clonal lymphoplasmacytic cells that produce monoclonal IgM. The disease may have an asymptomatic phase or patients may present with symptoms and complications due to marrow or other tissue infiltration or due to physicochemical or immunological properties of the monoclonal IgM. Diagnosis of WM has been clearly defined and genetic testing for somatic mutation of MYD88L265P is a useful tool for the deferential diagnosis from other conditions and specific criteria that define symptomatic disease that needs treatment offer clinical guidance. The treatment of WM has evolved rapidly, with treatment options that include anti-CD20 monoclonal antibody-based combinations and BTK inhibitors. The choice of therapy is based on the need for a rapid disease control, presence of specific disease complications and patient's age. With the use of BTK inhibitors, the use of continuous therapy has been introduced as another option over fixed duration therapy. In this review we will focus on different clinical scenarios and discuss treatment options, based on the available data.This publication has 95 references indexed in Scilit:
- Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemiaHaematologica, 2012
- Progression in smoldering Waldenström macroglobulinemia: long-term resultsBlood, 2012
- Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemiaCancer, 2011
- Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström MacroglobulinemiaJournal of Clinical Oncology, 2010
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003Blood, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemiaCancer, 2004
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003